Gene · 5420
PODXL: podocalyxin like
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PODXL: podocalyxin like. Genes, record 5420. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5420
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00592 | Podocalyxin | 558 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents53
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026078491 A | 2026-05-14 | 2 | O00592 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58282 | O00592 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10055 | O00592 | Espacenet |
| US 12473600 B2 | 2025-11-18 | 2 | O00592 | Espacenet |
| EP 4636080 A1 | 2025-10-22 | 18 | O00592 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3553 | O00592 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3553 | O00592 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10055 | O00592 | Espacenet |
| US 12024722 B2 | 2024-07-02 | 114 | O00592 | Espacenet |
| KR 1020240005121 A | 2024-01-11 | 2 | O00592 | Espacenet |
1 to 10 of 53
See all 53 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,491
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PODXL papers | Newest fiscal year |
|---|---|---|---|
| R01DK072381 | Kidney Injury Molecule-1 in Epithelial Repair | 8 | 2025 |
| R01DK039773 | Mechanisms of Ischemic Kidney Injury and Repair | 6 | 2025 |
| R24HD000836 | Laboratory of Developmental Biology | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R01CA227942 | Targeting the cancer glycocalyx | 4 | 2025 |
| R01DK076077 | Adaptive and maladaptive repair after kidney injury | 4 | 2025 |
| R01HL155921 | Polarized Protein Trafficking and Angiogenesis | 4 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 3 | 2025 |
1 to 10 of 1,491Source NIH's project files
See all 1,491 nih grantsPapers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies. | Stem Cells Transl Med | 2026 | 42768826 | PubTator, text mining | PubMed |
| A randomised controlled study of canagliflozin in improving diabetic kidney disease through a podocyte protection mechanism. | Ann Acad Med Singap | 2026 | 42745596 | PubTator, text mining | PubMed |
| Reassembly of Human Kidney Organoids after Dissociation. | Nephron | 2026 | 42715132 | PubTator, text mining | PubMed |
| Podocalyxin as biomarker for early detection of preeclampsia: A systematic review and meta-analysis. | Pregnancy Hypertens | 2026 | 42710171 | PubTator, text mining | PubMed |
| Modulating the sialic acid content of endothelial cells affects their adhesion and barrier permeability. | Sci Rep | 2026 | 42618733 | PubTator, text mining | PubMed |
| Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers. | Front Pharmacol | 2026 | 42518347 | PubTator, text mining | PubMed |
| Urinary podocalyxin as an early biomarker for diabetic nephropathy. | PLoS One | 2026 | 42490553 | PubTator, text mining | PubMed |
| Evaluation of serum moesin and podocalyxin levels in patients with diabetes mellitus. | Open Med (Wars) | 2026 | 42404647 | PubTator, text mining | PubMed |
| Persistent postpartum proteinuria, renal dysfunction, and future chronic kidney disease risk in women with preeclampsia. | Pregnancy Hypertens | 2026 | 42378806 | PubTator, text mining | PubMed |
| Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells. | BMC Cancer | 2026 | 42343334 | PubTator, text mining | PubMed |
1 to 10 of 2,215
See all 2,215 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5420
GET https://conductscience.org/api/genes/v1/5420/patents?page=2